Clinical Trials
38 trialsNCT06998940 2026-05-22
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07409272 2026-05-18
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
NCT04233866 2026-05-05
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06958328 2026-05-04
LAP100
NRG Oncology
Phase 3 Recruiting
NCT06625320 2026-04-27
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07542002 2026-04-21
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
Phase 2 Recruiting
NCT04390399 2025-12-15
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03693677 2025-07-01
FUNGEMAX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT05277766 2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1 Recruiting
NCT07026123 2025-06-18
A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China
RenJi Hospital
Not yet recruiting
NCT03468335 2025-04-17
PREDICT
AIO-Studien-gGmbH
Phase 3 Completed
NCT06766019 2025-01-09
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT06700603 2024-11-22
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06475326 2024-08-09
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Fudan University
Phase 2 Recruiting
NCT02697058 2024-07-25
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Servier
Phase 2 Completed
NCT06513455 2024-07-22
Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer
Harbin Medical University
Phase 1/2 Not yet recruiting
NCT04371224 2024-04-19
NaliCap
Seoul National University Hospital
Phase 2 Unknown
NCT06370754 2024-04-17
FD-IMPACT
Fudan University
Phase 1/2 Not yet recruiting
NCT06361316 2024-04-11
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT06259058 2024-03-15
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Not yet recruiting
NCT06210360 2024-01-18
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
Phase 2 Not yet recruiting
NCT04617457 2024-01-12
HOLIPANC
University of Cologne
Phase 2 Unknown
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05363007 2023-10-16
SINAI
National Taiwan University Hospital
Phase 2 Unknown
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT01926197 2022-10-28
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University
Phase 3 Completed
NCT02551991 2022-10-10
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
Phase 2 Completed
NCT03883919 2022-10-05
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
Phase 1 Completed
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03446872 2021-09-28
Post Marketing Surveillance Study for ONIVYDE® in South Korea
Servier
Completed
NCT03703063 2021-01-27
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Phase 1 Unknown
NCT03986294 2021-01-15
NAPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown
NCT03207724 2020-12-30
OnFX
Cedars-Sinai Medical Center
Phase 1 Completed
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT01494506 2016-06-17
NAPOLI-1
Merrimack Pharmaceuticals
Phase 3 Completed